0001104659-24-060006.txt : 20240510
0001104659-24-060006.hdr.sgml : 20240510
20240510172520
ACCESSION NUMBER: 0001104659-24-060006
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20240508
FILED AS OF DATE: 20240510
DATE AS OF CHANGE: 20240510
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Mika Yuval
CENTRAL INDEX KEY: 0001949285
ORGANIZATION NAME:
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-39421
FILM NUMBER: 24936120
MAIL ADDRESS:
STREET 1: 150 UNION SQUARE DRIVE
CITY: NEW HOPE
STATE: PA
ZIP: 18938
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Orchestra BioMed Holdings, Inc.
CENTRAL INDEX KEY: 0001814114
STANDARD INDUSTRIAL CLASSIFICATION: SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841]
ORGANIZATION NAME: 08 Industrial Applications and Services
IRS NUMBER: 000000000
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 150 UNION SQUARE DRIVE
CITY: NEW HOPE
STATE: PA
ZIP: 18938
BUSINESS PHONE: 646-343-9298
MAIL ADDRESS:
STREET 1: 150 UNION SQUARE DRIVE
CITY: NEW HOPE
STATE: PA
ZIP: 18938
FORMER COMPANY:
FORMER CONFORMED NAME: Health Sciences Acquisitions Corp 2
DATE OF NAME CHANGE: 20200603
4
1
tm2414108-7_4seq1.xml
OWNERSHIP DOCUMENT
X0508
4
2024-05-08
0
0001814114
Orchestra BioMed Holdings, Inc.
OBIO
0001949285
Mika Yuval
C/O ORCHESTRA BIOMED HOLDINGS, INC.
150 UNION SQUARE DRIVE
NEW HOPE
PA
18938
0
1
0
0
See Remarks
0
Common Stock, par value $0.0001 per share ("Common Stock")
2024-05-08
4
A
0
69333
0
A
158905
D
Represents an award of restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of Common Stock. The RSUs vest as follows: (i) 10,400 RSUs will vest on May 18, 2025, and (ii) the remaining 58,933 RSUs will vest in equal installments on August 18, 2025, November 18, 2025, December 18, 2025, May 18, 2026, August 18, 2026, November 18, 2026, March 25, 2027, May 18, 2027, August 18, 2027, November 18, 2027, March 25, 2028 and May 18, 2028, subject to the Reporting Person's continuous service through such dates.
General Manager and Chief Technology Officer, Bioelectronic Therapies
/s/ Matthew R. Schob, Attorney-in-Fact
2024-05-10